NCT04891653View on ClinicalTrials.gov

A Phase I Study of BR790 in Subjects With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

BR790

Subjects will receive oral administration of BR790.

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY